Clinical Trial Update: Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial evaluating the safety and feasibility of CD19 CAR T cells manufactured with the CliniMACS Prodigy platform for relapsed/refractory CD19-pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• CD19 CAR T cells (CliniMACS Prodigy) (CD19 CAR T cell therapy)

Snippet

Sponsor: Nationwide Children's Hospital | Conditions: Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed | EARLY_Phase 1 | Status: NOT_YET_RECRUITING